Search research articles
Contact Us
Filters
Showing results (351-360 of 404) with videos related to
Page
of 41
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"
A Vogel, A Cervantes, I Chau, et al.
Transplantation Proceedings
|
June 24, 1998
A randomized trial comparing anti-interleukin-2 receptor antibody and placebo for immunosuppressive therapy after OLT
J M Langrehr, M Glanemann, A Schneller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2022
Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]
A Vogel, A Cervantes, I Chau, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
Y Rotman, B B Borg, A Soza, et al.
AIDS Research and Human Retroviruses
|
January 11, 2008
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients
Veronique Nussenblatt, Mary McLaughlin, Catherine A Rehm, et al.
Plos One
|
March 11, 2011
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
Martin Lagging, Galia Askarieh, Francesco Negro, et al.
Cell
|
May 22, 2020
Paleolithic to Bronze Age Siberians Reveal Connections with First Americans and across Eurasia
He Yu, Maria A Spyrou, Marina Karapetian, et al.
Journal of Hepatology
|
February 21, 2006
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
Vincent G Bain, Kelly D Kaita, Eric M Yoshida, et al.
The Journal of Infectious Diseases
|
September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
Ana I Romero, Martin Lagging, Johan Westin, et al.
BMC Gastroenterology
|
February 2, 2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
Geert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, et al.
Page
of 41
Search research articles
Search
Showing results (351-360 of 404) with videos related to
Sort By:
Page
of 41
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"
A Vogel, A Cervantes, I Chau, et al.
Transplantation Proceedings
|
June 24, 1998
A randomized trial comparing anti-interleukin-2 receptor antibody and placebo for immunosuppressive therapy after OLT
J M Langrehr, M Glanemann, A Schneller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2022
Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]
A Vogel, A Cervantes, I Chau, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
Y Rotman, B B Borg, A Soza, et al.
AIDS Research and Human Retroviruses
|
January 11, 2008
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients
Veronique Nussenblatt, Mary McLaughlin, Catherine A Rehm, et al.
Plos One
|
March 11, 2011
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
Martin Lagging, Galia Askarieh, Francesco Negro, et al.
Cell
|
May 22, 2020
Paleolithic to Bronze Age Siberians Reveal Connections with First Americans and across Eurasia
He Yu, Maria A Spyrou, Marina Karapetian, et al.
Journal of Hepatology
|
February 21, 2006
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
Vincent G Bain, Kelly D Kaita, Eric M Yoshida, et al.
The Journal of Infectious Diseases
|
September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
Ana I Romero, Martin Lagging, Johan Westin, et al.
BMC Gastroenterology
|
February 2, 2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
Geert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, et al.
Page
of 41